Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Witkin

Showing results (141-150 of 321) with videos related to

Pageof 33
Sort By:
Expert Review of Clinical Pharmacology|March 31, 2023
Clinical pharmacological innovation in the treatment of depressionJeffrey M Witkin, Lalit K Golani, Jodi L Smith
NIDA Research Monograph|January 1, 1991
Lack of a genetic correlation between the convulsant and epileptogenic effects of cocaine and lidocaineJ M Witkin, S R Goldberg, R J Marley
Psychopharmacology|January 1, 1988
Environmental influences on the development of tolerance to the effects of physostigmine on schedule-controlled behaviorR F Genovese, T F Elsmore, J M Witkin
Behavioural Pharmacology|September 9, 2005
A role for cannabinoid CB1 receptors in mood and anxiety disordersJ M Witkin, E T Tzavara, G G Nomikos
Psychopharmacology|January 1, 1992
Reinforcing effects of enantiomers of N,N-dimethylamphetamine in squirrel monkeysJ L Katz, G A Ricaurte, J M Witkin
Life Sciences|January 1, 1989
Lethal effects of cocaine are reduced by the dopamine-1 receptor antagonist SCH 23390 but not by haloperidolJ M Witkin, S R Goldberg, J L Katz
Pharmacology, Biochemistry, and Behavior|January 1, 1989
Physostigmine-insensitive behavioral excitatory effects of atropine in squirrel monkeysJ M Witkin, R A Markowitz, J E Barrett
Psychopharmacology|January 1, 1988
Anxiolytic properties of amygdaloid kindling unrelated to benzodiazepine receptorsJ M Witkin, M A Lee, D D Walczak
The Journal of Pharmacology and Experimental Therapeutics|April 30, 2025
Is there a continued need for behavioral pharmacology in the discovery and development of medicines?Jeffrey M Witkin, Jodi L Smith, Daniel P Radin
The Journal of Pharmacology and Experimental Therapeutics|December 1, 1995
Discriminative stimulus effects of R-(+)-3-amino-1-hydroxypyrrolid-2-one, [(+)-HA-966], a partial agonist of the strychnine-insensitive modulatory site of the N-methyl-D-aspartate receptorJ M Witkin, S Brave, D French, et al.
Pageof 33

Showing results (141-150 of 321) with videos related to

Sort By:
Pageof 33
Expert Review of Clinical Pharmacology|March 31, 2023
Clinical pharmacological innovation in the treatment of depressionJeffrey M Witkin, Lalit K Golani, Jodi L Smith
NIDA Research Monograph|January 1, 1991
Lack of a genetic correlation between the convulsant and epileptogenic effects of cocaine and lidocaineJ M Witkin, S R Goldberg, R J Marley
Psychopharmacology|January 1, 1988
Environmental influences on the development of tolerance to the effects of physostigmine on schedule-controlled behaviorR F Genovese, T F Elsmore, J M Witkin
Behavioural Pharmacology|September 9, 2005
A role for cannabinoid CB1 receptors in mood and anxiety disordersJ M Witkin, E T Tzavara, G G Nomikos
Psychopharmacology|January 1, 1992
Reinforcing effects of enantiomers of N,N-dimethylamphetamine in squirrel monkeysJ L Katz, G A Ricaurte, J M Witkin
Life Sciences|January 1, 1989
Lethal effects of cocaine are reduced by the dopamine-1 receptor antagonist SCH 23390 but not by haloperidolJ M Witkin, S R Goldberg, J L Katz
Pharmacology, Biochemistry, and Behavior|January 1, 1989
Physostigmine-insensitive behavioral excitatory effects of atropine in squirrel monkeysJ M Witkin, R A Markowitz, J E Barrett
Psychopharmacology|January 1, 1988
Anxiolytic properties of amygdaloid kindling unrelated to benzodiazepine receptorsJ M Witkin, M A Lee, D D Walczak
The Journal of Pharmacology and Experimental Therapeutics|April 30, 2025
Is there a continued need for behavioral pharmacology in the discovery and development of medicines?Jeffrey M Witkin, Jodi L Smith, Daniel P Radin
The Journal of Pharmacology and Experimental Therapeutics|December 1, 1995
Discriminative stimulus effects of R-(+)-3-amino-1-hydroxypyrrolid-2-one, [(+)-HA-966], a partial agonist of the strychnine-insensitive modulatory site of the N-methyl-D-aspartate receptorJ M Witkin, S Brave, D French, et al.
Pageof 33